Major depressive disorder (MDD), a serious mood disorder that causes significant morbidity and mortality, affects over 300 million people worldwide1. MDD is characterized by low mood, reduced drive, loss of interest, and thoughts of self-harm or suicide2. Cognitive symptoms and sleep disturbance (SD) are two non-mood-related symptoms of MDD3,4. Previous studies have shown that the prevalence of SD is 60-90% in patients with MDD, while the prevalence of sleep disorders among these patients in the Chinese population is 85.22%5.
Although few studies have investigated the causal relationship between cognitive symptoms and SD, preliminary evidence suggests a significant association between sleep disorders and cognitive symptoms in individuals with MDD6. For example, Cha et al.3 found that subjective sleep quality predicted both subjective cognitive performance and objective cognitive impairments, which were partially mediated by depression severity. Biddle et al.7 also found that among older men with MDD, poor sleep efficiency (SE), measured by actigraphy, was associated with worse cognitive function independent of depression severity. The observed discrepancies may be caused by methodological differences.
Within this literature, researchers have used various tools to evaluate sleep and cognition. The Pittsburgh Sleep Quality Index (PSQI) was commonly selected as a subjective tool. Actigraphic devices have also been used. However, PSG, regarded as the gold standard for detecting sleep disorders8, is a sensitive, objective SD assessment9. To our knowledge, among the studies of the relationship between sleep and cognition in patients with MDD, few have used PSG to evaluate sleep quality.
Cognitive symptoms in MDD might be multidimensional and addressed in some cases by new pharmacological strategies10,11. Several cognitive assessment tools suitable for MDD have emerged in recent years12. THINC-integrated tool (THINC-it; henceforth referred to as the cognitive screening tool), a validated cognitive screening tool developed by Hou et al.13, is composed of a subjective questionnaire (perceived deficits questionnaire, PDQ-5) and four objective cognitive tests (choice reaction time, 1-back, digit symbol substitution, and trail making part-B). It is considered a time-efficient, acceptable method for detecting cognitive deficits in patients with MDD14. There are two other tools commonly used to assess cognitive function in patients with MDD: the Screen for Cognitive Impairments in Psychiatry-D (SCIP-D) and Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA)12. The former is an objective tool lacking self-instructed testing, and the latter is a subjective tool lacking an objective version. The constituent tests also differ between these tools. The SCIP-D is comprised of five objective tests: verbal learning, working memory, verbal fluency, delayed memory, and processing speed. The COBRA includes executive function, processing speed and attention, verbal learning and memory, and visual memory12. The recently developed Chinese version of the cognitive screening tool has been confirmed to be a good tool for evaluating cognitive deficits in Chinese patients with MDD15. Thus, using the cognitive screening tool software and PSG, the current study tried to reveal the relationship between cognitive symptoms and SD in MDD patients.